) is a topoisomerase Ⅰinhibitor, and effective in small cell lung cancer (SCLC). The objective of this study is to compare the efficacy and safety of belotecan+cisplatin (BP) and etoposide+cisplatin (EP) in first line setting.
Methods: This is a multicenter, randomized, prospective controlled trial to prove non-inferiority of BP compared to standard EP regimen. The primary endpoint is overall response rate (ORR), and secondary endpoints are toxicity, overall survival and progression-free survival. BP was administrated by belotecan 0.5 mg/m 2 for 4 days combined with cisplatin 60 mg/m 2 only for first day. Treatment response was evaluated according to version 1.0 of Response Evaluation Criteria in Solid Tumors.
Results: We enrolled 133 (BP: 67, EP: 66) patients, and response evaluation was possible in 88 (BP: 40, EP: 48) patients.
In BP group, there were 1 complete response, 25 partial responses (PR), 9 stable diseases (SD), and there were 2 PR and 8 SD in EP group. There were no significant differences in ORR (BP: 65.0%, EP: 66.7%, p=1.000) and disease control rate (BP: 87.5%, EP: 83.3%, p=0.765). The frequency of grade ≥3 hematologic toxicities (BP: 52.4%, EP: 47.7%) and non-hematologic toxicities (BP: 28.6%, EP: 21.5%) were not significantly different. The most common hematologic and non-hematologic toxicities were neutropenia and hyponatremia, respectively.
Conclusions:
In this interim analysis, BP and EP have similar ORR and safety profiles in extensive stage SCLC.
